Xcout IntelErasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Subscribe to see Erasca, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Erasca, Inc. at a glance
Erasca, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (ERAS) with a market capitalisation of $5.1B. Xcout tracks 19 named people at Erasca, Inc., including Nik Chetwyn (Chief Operating Officer). Xcout recorded 20 job postings from Erasca, Inc. in the last 90 days.
Erasca, Inc. leadership
- Nik ChetwynChief Operating Officer
- David ChackoChief Financial Officer & Chief Business Officer
- Shannon MorrisChief Medical Officer
- Ebun S. GarnerChief Legal Officer & Corporate Secretary
- Lisa Tesvich-BonoraChief People Officer
- Robert ShoemakerChief Scientific Officer
13 more named people on record for Erasca, Inc., with roles, board committees and tenure — see the full roster →
Erasca, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $236M | — | |
| — | $64M | 2 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Erasca, Inc.
Xcout recorded 20 job postings from Erasca, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Erasca, Inc.'s hiring signals →
Recent Erasca, Inc. news
3 corporate events on record, with sources — see the full timeline →
Investors
Erasca, Inc. competitors
A few of Erasca, Inc.'s closest competitors — see the full list of competitors and alternatives →
Quanta Therapies is a biopharmaceutical company that develops allosteric small molecule inhibitors targeting RAS-driven cancers, such as pancreatic, colorectal, lung, and endometrial cancers. The company focuses on modulating RAS signaling at the cell membrane to treat previously undruggable mutations like KRAS G12D and KRAS G12V.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Revolution Medicines is a biotechnology research company headquartered in Redwood City, California. Its mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines, translating frontier oncology targets.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Get Erasca, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Erasca, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Erasca, Inc. in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access